NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ZYNE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.26▼$1.3450-Day Range$1.21▼$1.3952-Week Range$0.25▼$1.40Volume862,700 shsAverage Volume515,333 shsMarket Capitalization$70.12 millionP/E RatioN/ADividend YieldN/APrice Target$1.11 Stock AnalysisStock Analysis Get Zynerba Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ZYNE Stock News HeadlinesOctober 31, 2023 | finance.yahoo.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 13, 2023 | fool.comWhy Shares of Harmony Bioscience Are Falling on FridayApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. October 11, 2023 | markets.businessinsider.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | finance.yahoo.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 4, 2023 | finance.yahoo.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsSeptember 29, 2023 | finance.yahoo.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023April 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. September 27, 2023 | bizjournals.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 14, 2023 | finance.yahoo.comInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncSeptember 14, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumAugust 16, 2023 | msn.comHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)August 15, 2023 | finance.yahoo.comIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?August 14, 2023 | marketwatch.comZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEAugust 14, 2023 | markets.businessinsider.comCrude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike HigherAugust 14, 2023 | technews.tmcnet.comZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 14, 2023 | finance.yahoo.comHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.July 25, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces New Date for Reconvened Annual MeetingJune 29, 2023 | finance.yahoo.comZynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?June 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Further Adjournment of Annual MeetingJune 20, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceJune 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Partial Adjournment of Annual MeetingMay 17, 2023 | bizjournals.comMain Line CBD drug developer plans reverse stock split to boost share priceMay 15, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | investing.comZynerba Pharma (ZYNE) Earnings Dates & ReportsMay 15, 2023 | msn.comZynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The DetailsSee More Headlines Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$1.11 High Stock Price Target$1.11 Low Stock Price Target$1.11 Potential Upside/Downside-14.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.03% Return on Assets-72.62% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.29Miscellaneous Outstanding Shares53,939,000Free Float46,905,000Market Cap$70.12 million OptionableOptionable Beta1.32 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Armando Anido MBA (Age 65)Chairman & CEO Comp: $934.53kMs. Terri B. Sebree (Age 65)Pres Comp: $729.15kMr. James E. Fickenscher (Age 59)CFO & VP of Corp. Devel. (Leave of Absence) Comp: $607.62kMr. Kenneth T. Jones (Age 59)VP, Corp. Controller & Interim CFO Mr. Albert P. Parker II (Age 57)Chief Legal Officer & Corp. Sec. Mr. Joseph ApostolicoVP of HRMore ExecutivesKey CompetitorsJourney MedicalNASDAQ:DERMCarisma TherapeuticsNASDAQ:CARMAnebulo PharmaceuticalsNASDAQ:ANEBLandos BiopharmaNASDAQ:LABPAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInsidersArmando AnidoSold 17,830 sharesTotal: $23,713.90 ($1.33/share)Terri B SebreeSold 12,401 sharesTotal: $16,493.33 ($1.33/share)James E FickenscherSold 8,998 sharesTotal: $11,967.34 ($1.33/share)Brian RosenbergerSold 6,411 sharesTotal: $8,526.63 ($1.33/share)Kenneth T JonesSold 2,505 sharesTotal: $3,331.65 ($1.33/share) ZYNE Stock Analysis - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price target for 2024? 3 brokerages have issued twelve-month target prices for Zynerba Pharmaceuticals' stock. Their ZYNE share price targets range from $1.11 to $1.11. On average, they predict the company's stock price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 14.6%. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? Zynerba Pharmaceuticals (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. This page (NASDAQ:ZYNE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
